Press

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

Oct 13 • 4 min read

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that its RELIANCE III study (REL-1017-303), evaluating REL-1017 in the monotherapy setting for Major Depressive Disorder (MDD), did not achieve its primary endpoint, which was a statistically significant improvement in depression symptoms compared to placebo as…

Field Trip Announces Relaunch and Refresh of Its Award-Winning Psychedelic App

Oct 13 • 3 min read

Field Trip Health & Wellness Ltd. (TSX-V: FTHW), the global leader in the development and delivery of psychedelic therapies, is pleased to announce that a new version of its award-winning app for psychedelic guidance is now available for download on the App Store and Google Play. Formerly known as ‘Trip’ and now known simply as ‘Field Trip’, the…

Clairvoyant’s Phase 2 Psilocybin Therapy Trial for Alcohol Use Disorder Obtains Regulatory Approval and Initiates 1st Clinical Site in Finland

Oct 13 • 3 min read

Clairvoyant Therapeutics, a Canadian biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce it has received regulatory approval from the Finnish Medicines Agency (FIMEA) to proceed with the company’s Phase 2 clinical trial investigating psilocybin, a compound found in psychedelic mushrooms, for the treatment of…

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

Oct 12 • 4 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in treatment resistant depression (TRD) during a virtual Capital Markets Day. The session, attended by members of COMPASS Pathways’ executive leadership and…

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

Oct 12 • 3 min read

atai Life Sciences N.V. (Nasdaq: ATAI) announced today positive initial results for their Phase 1 clinical trial of KUR-101. KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD). Initial results indicate that KUR-101 is safe and generally well-tolerated….

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441